Potter exits Genentech after medical problemsGenentech's Myrtle Potter has stepped down from her post as president of commercial operations following a series of medical problems. She will continue to serve as a consultant to the company, Genentech said.
Potter will be succeeded by Ian Clark, senior vice president and general manager of BioOncology who has been running commercial operations in an acting role for the past eight months.
Potter joined Genentech in 2000 as executive vice president and chief operating officer and has overseen the successful launch of six new products including, Avastin, Raptiva, Xolair, Nutropin AQ Pen, Cathflo Activase, and TNKase. In March 2004 she was promoted to president of commercial operations.
Potter had been on leave since late December, a fact the company had not formally disclosed until this week.